Scientists at the University of Cambridge, led by Professor Matthias Zilbauer, have grown 'mini-guts' to study Crohn's disease.

These organoids were created using cells from inflamed guts of patients, including 11-year-old Arthur Hatt.

The study revealed the crucial role of epigenetic changes in the DNA of gut cells and the significance of the MHC-I pathway in Crohn's disease.

The research, published in Gut, aims to develop personalized treatments based on patients' specific genetic markers.

Environmental factors such as infections and antibiotics may contribute to epigenetic changes, potentially explaining the recurrence of inflammation after treatment.

Epigenetic patterns in Crohn's patients were found to correlate with disease severity, offering hope for improved therapies.

A patent has been filed for the technology, with commercial partners being sought for further development.

Arthur Hatt's story highlights the impact of Crohn's disease on children and the need for tailored treatments.